Advertisement

Search Results

Advertisement



Your search for ASCO matches 14188 pages

Showing 201 - 250


New James Cancer Diagnostic Center to Expedite Access to Diagnostic Testing

A recently opened center at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) gives patients direct, expedited access to diagnostic testing for cancer. The goal, said Chief Medical Officer David Cohn, MD,...

The Piano

The ASCO Post is pleased to reproduce installments of the Art of Oncology, as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...

Cancer Genome Atlas Founding Members and Current Project Team Awarded 2020 AACR Team Science Awards

During its recent Virtual Annual Meeting II, the American Association for Cancer Research (AACR) presented its 2020 Team Science Awards to the founding members and the current project team associated with The Cancer Genome Atlas (TCGA). TCGA began in 2006 as a joint effort between the National...

Kunle Odunsi, MD, PhD, FRCOG, FACOG, Elected At-Large Director of SITC Board of Directors

Elected by a body of fellow immunotherapy researchers from across the globe, Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, has been named At-Large Director of the Society for Immunotherapy of Cancer (SITC) Board of Directors. Dr. Odunsi will begin his ...

lung cancer

Do Not Rush to High-Dose Twice-Daily Radiation for Limited Small Cell Lung Cancer

Bjørn Henning Gronberg, MD, PhD, presented a paper at the ASCO20 Virtual Scientific Program reporting astounding positive results favoring higher-dose, twice-daily radiation therapy in limited-stage small cell lung cancer.1 This was a phase II study (large for phase II but small for phase III)...

integrative oncology

Elderberry

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on...

prostate cancer
genomics/genetics

New Recommendations Offer Guidance for Clinicians and Patients on Genetic Testing for Prostate Cancer

An international panel of experts led by researchers and thought leaders at the Sidney Kimmel Cancer Center–Jefferson Health (SKCC) and the Department of Urology at Jefferson have published the first multidisciplinary, consensus-driven, prostate cancer genetic implementation framework for the...

hepatobiliary cancer
immunotherapy

IMbrave150: A New Standard of Care to Treat Hepatocellular Cancers?

In 2007, sorafenib became the first approved systemic therapy for hepatocellular cancers and the first agent to improve overall survival in these patients.1 In a similar multikinase inhibitor strategy, lenvatinib was found to be noninferior to sorafenib in overall survival in the same patient...

covid-19

FDA Collaborating on Use of Real-World Data to Inform COVID-19 Response Effort

On June 18, 2020, the U.S. Food and Drug Administration (FDA) took an additional step in harnessing real-world data to help inform the agency’s overall response to the COVID-19 public health emergency. The FDA announced its participation in the COVID-19 Diagnostics Evidence Accelerator, a...

palliative care

A Palliative Care Specialist Explores What It Means to Live and Die With Dignity and Purpose

Palliative care’s road to acceptance as standard-of-care practice has been a remarkably unsmooth one, given its core mission: improving the quality of life of patients and their families by relieving the pain, symptoms, and stress of a serious or life-limiting illness. A person’s relationship with...

AACR Recognizes Achievements of Three Cancer Researchers

The American Association for Cancer Research (AACR) is honoring three clinical cancer researchers for their outstanding achievements. Jedd D. Wolchok, MD, PhD, FASCO, will receive the 2020 AACR–Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research. Lisa A. Newman, MD,...

Jessica Karen Wong, MD, MEng, Joins Radiation Oncology Department at Fox Chase

Fox Chase Cancer Center announced that Jessica Karen Wong, MD, MEng, recently joined the Department of Radiation Oncology as Assistant Professor in the academic clinician track. Dr. Wong completed her radiation oncology residency program at Fox Chase, where she served as Chief Resident in 2019 and...

bladder cancer
immunotherapy

Expert Point of View: Daniel Y. Heng, MD, MPH, and Toni K. Choueiri, MD

Study discussant Daniel Y. Heng, MD, MPH, a medical oncologist at Tom Baker Cancer Centre, University of Calgary, Canada, called the negative trial results important. IMvigor010 randomly assigned patients with high-risk muscle-invasive urothelial carcinoma to adjuvant atezolizumab or observation...

breast cancer
immunotherapy

Roundup of High-Impact Studies in Early Breast Cancer

Clinicians interested in breast cancer who logged into the ASCO20 Virtual Scientific Program were greeted with an abundance of high-impact presentations. The ASCO Post has reported on several studies in depth elsewhere, but here we offer our readers a roundup of several important studies in early...

geriatric oncology

Geriatric Assessment: What Are You Waiting For?

The ASCO20 Virtual Scientific Program was the forum for an unusual but profoundly important event in oncology. Four studies that should be practice-changing were presented.1-4 These studies provided irrefutable evidence that we can improve the quality of life of older patients by reducing toxicity. ...

multiple myeloma
immunotherapy

Expert Point of View: Philip McCarthy, MD

Philip McCarthy, MD, Professor of Oncology and Internal Medicine and Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, Buffalo, New York, found the results of the DREAMM-6 study to be “exciting and promising.” He commented: “The overall response...

AACR Recognizes New 2019–2020 Research Grantees

The American Association for Cancer Research (AACR) has announced its newest class of grant recipients. Fellowships The 2019 Anna D. Barker Fellowship in Basic Cancer Research was awarded to Chaoyun Pan, PhD, of Emory University, Atlanta, and Conghui Yao, PhD, of Harvard Medical School, Cambridge....

lung cancer

Lung Cancer Research Foundation Names Trudy Oliver, PhD, to Its Scientific Advisory Board

The Lung Cancer Research Foundation (LCRF) recently announced that Trudy Oliver, PhD, has joined its Scientific Advisory Board. Dr. Oliver is Associate Professor of Oncological Sciences at the University of Utah’s Huntsman Cancer Institute (HCI), where she has served since 2011, and is an HCI...

lung cancer
immunotherapy

Phase II Study Evaluates Chemotherapy and Immunotherapy in Patients With Malignant Pleural Mesothelioma

Data from the phase II PrE0505 multicenter trial showed that adding durvalumab, an immune checkpoint antibody targeting programmed cell death ligand 1 (PD-L1), to the combination of cisplatin and pemetrexed chemotherapy improved outcomes in previously untreated patients with unresectable malignant...

Her Grandfather’s Medical Practice Inspired Nathalie LeVasseur, MD, BSc, FRCPC, to Improve the Lives of Women With Breast Cancer

At the 2018 ASCO Annual Meeting, Nathalie LeVasseur, MD, BSc, FRCPC, received the Annual Meeting Merit Award for a project titled, “Whole-Genome Sequencing in Metastatic Breast Cancer: Lessons Learned From the BC Cancer Personalized Oncogenomics Program.” Along with her clinical work, Dr....

A New Website Offers Support for Adolescent and Young Adults With Cancer During the COVID-19 Pandemic

Although the full impact of the COVID-19 pandemic on patients with cancer is still being evaluated, data from several studies show that in comparison with people who do not have cancer, those who do generally experience a higher risk of severe events including admittance to the intensive care unit, ...

pain management

Understanding the Underlying Mechanisms of Pain in Patients With Cancer

Pain is among the most difficult medical issues for oncologists to confront, said Tony L. Yaksh, PhD, Professor of Anesthesiology and Pharmacology at the University of California, San Diego, during his keynote address at the 2019 Supportive Care in Oncology Symposium. Failure to adequately manage...

issues in oncology

Improving the Quality of Care and Research for Patients With Cancer and the Ethics Behind Its Delivery

With the rapid expansion of scientific advances, the intersection of ethics and the delivery of cancer care becomes ever more complicated. To shed light on some of the challenging ethical issues faced by today’s busy oncology practitioners, The ASCO Post spoke with Rebecca D. Pentz, PhD, Professor ...

Donor Spotlight: GO2 Foundation for Lung Cancer Unifies to Drive Change

In 2019, the GO2 Foundation for Lung Cancer was born from the merger of the Bonnie J. Addario Lung Cancer Foundation and the Lung Cancer Alliance. The marriage of two lung cancer advocacy groups raises the profile of each group’s work and combines considerable resources to combat lung cancer. The...

Conquer Cancer Grants More Than $8 Million to Cancer Research

Conquer Cancer, the ASCO Foundation, announced its 2020 grant and award recipients in conjunction with the 2020 ASCO Virtual Scientific Program. The awards will support researchers with projects spanning many areas in cancer care, including immunotherapy, lung and breast cancers, and palliative...

covid-19

ASCO COVID-19 Registry: Acceptable for MIPS Improvement Activity

ASCO’s Survey on COVID-19 in Oncology Registry (ASCO Registry) is an acceptable clinical trial registry for the attestation of the high-weighted practice Improvement Activity, “COVID-19 Clinical Trials Related to the Emergency Response & Preparedness,” under the Centers for Medicare &...

covid-19

Guidance Available on Telemedicine Coverage During COVID-19 Pandemic

Effective for services starting March 1, 2020, and for the duration of the COVID-19 emergency, the Centers for Medicare & Medicaid Services (CMS) will reimburse for telehealth services for all beneficiaries. To help explain this and other changes to telehealth coverage related to the pandemic,...

covid-19

2020 ASCO Presidential Address Focuses on ‘Unite and Conquer: Accelerating Progress Together’

The world is grappling with a pandemic and we are all adjusting to a new reality. Fewer handshakes, more masks. Fewer hugs, more fear. COVID-19 has tested us, challenged us, changed us. It’s changed the way we look, the way we work, the way we socialize. It’s changed us, but it can’t stop us. It...

Glenn D. Steele, Jr, MD, PhD, Named Chair of City of Hope Board of Directors

Health-care innovator and leader Glenn D. Steele Jr, MD, PhD, has been elected Board Chair at City of Hope. Dr. Steele joined the City of Hope Board of Directors in 2016 and was Chair of the Executive Compensation and Governance Committee from 2018 to 2020. “City of Hope has benefited from...

immunotherapy

New NCCN Guidelines Offer Patients Help in Recognizing Side Effects From Immunotherapy

The National Comprehensive Cancer Network (NCCN) recently announced the publication of “NCCN Guidelines for Patients: Immunotherapy Side Effects—Immune Checkpoint Inhibitors.” These new guidelines are designed to educate patients and to help them recognize immune side effects so effective...

ASCO Opens Search for Chief Medical Officer: Express Interest by August 21, 2020

ASCO is conducting an open search for the position of Chief Medical Officer and Executive Vice President, as current Chief Medical Officer, Richard L. Schilsky, MD, FACP, FSCT, FASCO, prepares to retire in February 2021. ASCO’s Chief Medical Officer applies his/her medical and scientific knowledge ...

Insomnia in Adolescent and Young Adult Cancer Survivors

Adolescents and young adults (AYA) who have survived cancer may continue to suffer from insomnia long after treatment ends, interfering with a range of daily activities. In Pediatric Blood & Cancer, Eric S. Zhou, PhD, and Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute,...

Society for Immunotherapy of Cancer Names Recipients of Memorial Award and Lectureship

The Society for Immunotherapy of Cancer (SITC) has announced three recipients of the 2020 Richard V. Smalley, MD, Memorial Award and Lectureship, the society’s highest honor: they include Lieping Chen, MD, PhD, Gordon Freeman, PhD, and Arlene Sharpe, MD, PhD. The research conducted by Drs....

health-care policy

Addressing Discrimination and Bias in Medical Education

“As a medical student, I often felt marginalized from my medical community. I have been told that my name is ‘not American,’ fallen prey to being confused for support staff such as a janitor (even while wearing my white coat), and been asked questions like, ‘Where are you really from?’ or ‘How old...

leukemia

Arnon P. Kater, MD, PhD, on CLL: Efficacy of Venetoclax in Relapsed or Refractory Disease

Arnon P. Kater, MD, PhD, of the University of Amsterdam, Cancer Center Amsterdam, discusses phase IIIb results from the VENICE I trial, which confirmed that venetoclax monotherapy can achieve deep responses and has a tolerable and manageable safety profile in patients with relapsed or refractory...

leukemia

Jorge E. Cortes, MD, on Chronic Phase CML: Comparing Three Starting Doses of Ponatinib

Jorge E. Cortes, MD, of Georgia Cancer Center, discusses interim results from the OPTIC study, which showed a trend toward dose-dependent efficacy and safety, and may provide a refined understanding of the ponatinib benefit/risk profile and its relation to dose. Mature data from continued follow-up ...

immunotherapy

Efstathios Kastritis, MD, on Amyloidosis: Daratumumab Plus Cyclophosphamide, Bortezomib, and Dexamethasone

Efstathios Kastritis, MD, of the University of Athens, discusses phase III findings of the Andromeda study. Adding daratumumab to cyclophosphamide, bortezomib, and dexamethasone resulted in deeper and more rapid hematologic responses and improved clinical outcomes in patients with newly diagnosed...

gynecologic cancers
immunotherapy

Addition of Trastuzumab to Carboplatin/Paclitaxel for Advanced or Recurrent HER2-Positive Uterine Serous Carcinoma

Combining the HER2-targeted therapy trastuzumab with carboplatin and paclitaxel improved survival rates for women with a rare, aggressive type of endometrial cancer, according to findings published by Fader et al in Clinical Cancer Research. Each year, more than 65,650 women in the United States...

head and neck cancer

Number of Hospitalizations May Be an Important Indicator of Survival for Patients With Head and Neck Cancer

Patients who were unexpectedly hospitalized for dehydration, fever, or other events while undergoing radiotherapy for head and neck cancer were at a higher risk for less favorable outcomes, according to a study published by Anurag K. Singh, MD, and colleagues in Oral Oncology. Researchers found...

lymphoma
immunotherapy

Elizabeth H. Phillips, MD, on DLBCL: Inotuzumab Ozogamicin Plus Chemotherapy in Front-Line Setting

Elizabeth H. Phillips, MD, of the University of Manchester and The Christie Hospital, discusses phase II findings showing inotuzumab ozogamicin plus rituximab, cyclophosphamide, vincristine, and prednisolone is a feasible and effective regimen for front-line treatment of high-risk patients with...

leukemia
lymphoma

John C. Byrd, MD, on CLL/SLL: Acalabrutinib in Treatment-Naive Patients

John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, discusses the mature results of a phase II study showing durable remissions and long-term tolerability of acalabrutinib in treatment-naive patients with relapsed or refractory chronic lymphocytic leukemia or small...

gynecologic cancers

Two Studies Report Secondary Surgery Extends Survival in Recurrent Ovarian Cancer

Two phase III trials provide support for secondary cytoreductive surgery in women with recurrent ovarian cancer, with the caveats that patient selection is key and the surgery should be performed at sites of excellence. The results of the DESKTOP III and SOC1 trials, both presented during the...

issues in oncology
colorectal cancer

Geographic Patterns of Early-Onset Colorectal Cancer Diagnoses in the United States

Over the past 3 decades, colorectal cancer survival in the United States has improved significantly, but in young people—particularly men diagnosed with colorectal cancer before age 50—incidence and mortality due to colorectal cancer are on the rise. Additionally, among patients with early-stage...

myelodysplastic syndromes

FDA Approves Oral Combination of Decitabine and Cedazuridine for Adult Patients With Myelodysplastic Syndromes

On July 7, the U.S. Food and Drug Administration (FDA) approved an oral combination of decitabine and cedazuridine (Inqovi) for adult patients with myelodysplastic syndromes (MDS), including the following: Previously treated and untreated de novo and secondary MDS with the following...

lung cancer

USPSTF Issues Draft Recommendation Statement on Screening for Lung Cancer

On July 7, the U.S. Preventive Services Task Force (USPSTF) posted a draft recommendation statement, draft evidence review, and draft modeling study on screening for lung cancer in people who do not have signs or symptoms. Based on the evidence, the USPSTF recommends annual screening using a...

hepatobiliary cancer

ESMO World GI: Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGFR2 Fusions

At the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 Virtual, Javle et al reported that third- and later-line treatment with the selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor infigratinib resulted in a progression-free survival and...

prostate cancer

Expert Point of View: Scott T. Tagawa, MD, MS

Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, agreed that prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) is the wave of the future, but data on long-term outcomes are needed, he said. “We are all aware of the deficiencies of imaging ...

gynecologic cancers

Expert Point of View: Don S. Dizon, MD, FACP, FASCO

Commenting on the SOLO2 trial for The ASCO Post was Don S. Dizon, MD, FACP, FASCO, Director of Women’s Cancers at Lifespan Cancer Institute and Professor of Medicine at Brown University, Providence, Rhode Island. “It’s great to get an overall survival advantage from a PARP inhibitor study. Coming...

skin cancer
immunotherapy

Longer-Term Results of Pivotal Study in Advanced Cutaneous Squamous Cell Carcinoma

New, longer-term data from a pivotal phase II trial in advanced cutaneous squamous cell carcinoma (CSCC), were presented during the ASCO20 Virtual Scientific Program and discussed during a poster discussion.1 Danny Rischin, MD, of the Peter MacCallum Cancer Centre, Victoria, Australia, presented...

prostate cancer

PSMA-Targeted PET/CT Imaging May Be Useful in Biochemically Recurrent Prostate Cancer

Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...

Advertisement

Advertisement



Advertisement